Shares of Gland Pharma gained about 5 percent on February 25, clocking its best day in 16 weeks, ahead of its investor meet on Feb 27-28 during the analyst day with Emkay and BoB Capital. This comes following the United States Food and Drug Administration (US FDA)
Pre-approval inspection (PAI) for Sterile APIs at the Company’s Facility at JNPC, Visakhapatnam between February 19, 2025 and February 25, 2025.
The inspection concluded with three (3) Form 483 observations, which are procedural in nature. Corrective and preventive actions for these observations will be submitted to the US FDA within the required timeframe. These observations are not repeats and are unrelated to data integrity issues.
Business daily Livemint had reported earlier this in February citing sources that Blackstone, Brookfield, and Warburg Pincus were in talks to acquire a majority stake in Gland Pharma, a maker of generic injectables. The deal, involving three global private equity majors and Shanghai-based Fosun Pharma - which holds a majority stake - is expected to value Gland Pharma at approximately $3 billion.
Gland Pharma's performance for the December quarter has been underwhelming, with weak revenue growth in its core business. The injectables company also faced challenges from its recently acquired Cenexi business, which weighed on its performance. Gland Pharma anticipates a recovery in its core business in Q4FY25 but has extended the breakeven timeline for Cenexi by another year.
Gland Pharma reported an 11 percent on-year rise in net profit at Rs 98 crore for the December quarter. Its revenue from operations saw a gain of about 38 percent on-year at Rs 1,271 crore, while total income climbed to Rs 1,343 crore.
Gland Pharma is a global supplier of medicines administered through vials, syringes, bags and pumps, with a major portion of its exports being led by the USA. As per forecasts, USA is expected to see a 10 percent growth in annual demand for injectables in the next five years.
Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
